As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Entrada Therapeutics, Inc. The largest reported stake is 5AM Ventures V, L.P.'s, at 10.8%. 7 filings are on record since August 14, 2025 (Schedule 13D/A, November 18, 2025).
Sell to companies like Entrada Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: MPM BioVentures 2014, L.P. · Sole voting: 1,764,167 · Shared voting: 0 · Sole dispositive: 1,764,167 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-10
- · Reporting person: TCG Crossover GP I, LLC · Sole voting: 0 · Shared voting: 1,060,230 · Sole dispositive: 0 · Shared dispositive: 1,060,230 · SCHEDULE 13G/A, 2026-08-14
- · Holder: TCG Crossover GP I, LLC · Percent: 5% · SCHEDULE 13G
- · Reporting person: 5AM Ventures V, L.P. · Sole voting: 0 · Shared voting: 2,963,066 · Sole dispositive: 0 · Shared dispositive: 2,963,066 · SCHEDULE 13D/A, 2025-11-18
- · Holder: T. Rowe Price Associates, Inc. · Percent: 0.9% · SCHEDULE 13G/A
Entrada Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 5AM Ventures V, L.P. | 10.8% | 2,963,066 | SCHEDULE 13D/A, 2025-11-18 | 2025-11-14 |
| MPM BioVentures 2014, L.P. | 9.9% | 1,764,167 | SCHEDULE 13D/A, 2026-09-10 | 2026-09-08 |
| Janus Henderson Group Plc | 4% | 1,521,281 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| TCG Crossover GP I, LLC | 2.7% | 1,060,230 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| T. Rowe Price Associates, Inc. | 0.9% | 360,526 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Entrada Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Entrada Therapeutics, Inc. and the records around it.
Entrada Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- 5AM Ventures V, L.P. also filed stake reports on 1 other company: Rallybio Corp (May 2026)
- MPM BioVentures 2014, L.P. also filed stake reports on 1 other company: WEREWOLF THERAPEUTICS, INC. (May 2026)
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Vistagen Therapeutics, Inc. (Aug 2026), Savara Inc. (Feb 2026)
Watch Entrada Therapeutics, Inc.
Get an email when Entrada Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Entrada Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Entrada Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Entrada Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P. | 0 | 2,963,066 | 0 | 2,963,066 | SCHEDULE 13D/A, 2025-11-18 |
| 5AM Partners V, LLC | 0 | 2,963,066 | 0 | 2,963,066 | SCHEDULE 13D/A, 2025-11-18 |
| 5AM Opportunities I, L.P. | 0 | 1,093,313 | 0 | 1,093,313 | SCHEDULE 13D/A, 2025-11-18 |
| 5AM Opportunities I (GP), LLC | 0 | 1,093,313 | 0 | 1,093,313 | SCHEDULE 13D/A, 2025-11-18 |
| Andrew J. Schwab | 0 | 4,056,379 | 0 | 4,056,379 | SCHEDULE 13D/A, 2025-11-18 |
| Kush Parmar | 67,470 | 4,056,379 | 67,470 | 4,056,379 | SCHEDULE 13D/A, 2025-11-18 |
| Scott M. Rocklage | 0 | 2,963,066 | 0 | 2,963,066 | SCHEDULE 13D/A, 2025-11-18 |
| MPM BioVentures 2014, L.P. | 1,764,167 | 0 | 1,764,167 | 0 | SCHEDULE 13D/A, 2026-09-10 |
| MPM BioVentures 2014 (B), L.P. | 117,667 | 0 | 117,667 | 0 | SCHEDULE 13D/A, 2026-09-10 |
| MPM Asset Management Investors BV2014 LLC | 60,722 | 0 | 60,722 | 0 | SCHEDULE 13D/A, 2026-09-10 |
| MPM BioVentures 2014 GP LLC | 0 | 1,881,834 | 0 | 1,881,834 | SCHEDULE 13D/A, 2026-09-10 |
| MPM BioVentures 2014 LLC | 0 | 1,942,556 | 0 | 1,942,556 | SCHEDULE 13D/A, 2026-09-10 |
| Mpm Bioventures 2018, L.P. | 1,810,592 | 0 | 1,810,592 | 0 | SCHEDULE 13D/A, 2026-09-10 |
| Mpm Bioventures 2018 (B), L.P. | 96,232 | 0 | 96,232 | 0 | SCHEDULE 13D/A, 2026-09-10 |
| Mpm Asset Management Investors Bv2018 LLC | 35,735 | 0 | 35,735 | 0 | SCHEDULE 13D/A, 2026-09-10 |
| MPM BioVentures 2018 GP LLC | 0 | 1,906,824 | 0 | 1,906,824 | SCHEDULE 13D/A, 2026-09-10 |
| MPM BioVentures 2018 LLC | 0 | 1,942,559 | 0 | 1,942,559 | SCHEDULE 13D/A, 2026-09-10 |
| Ansbert Gadicke | 0 | 3,885,115 | 0 | 3,885,115 | SCHEDULE 13D/A, 2026-09-10 |
| Luke Evnin | 0 | 3,885,115 | 0 | 3,885,115 | SCHEDULE 13D/A, 2026-09-10 |
| Todd Foley | 0 | 3,885,115 | 0 | 3,885,115 | SCHEDULE 13D/A, 2026-09-10 |
| TCG Crossover GP I, LLC | 0 | 1,060,230 | 0 | 1,060,230 | SCHEDULE 13G/A, 2026-08-14 |
| TCG Crossover Fund I, L.P. | 0 | 1,060,230 | 0 | 1,060,230 | SCHEDULE 13G/A, 2026-08-14 |
| Chen Yu | 0 | 1,060,230 | 0 | 1,060,230 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Entrada Therapeutics, Inc. by CUSIP 29384C108 and gives its principal executive office as ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA 02210 (SCHEDULE 13D/A, 2026-09-10).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | T. Rowe Price Associates, Inc. | 6.8% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 4% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 0.9% | SCHEDULE 13G/A |
| 2025-11-18 | 5AM Ventures V, L.P. | 10.8% | SCHEDULE 13D/A |
| 2025-11-25 | TCG Crossover GP I, LLC | 5% | SCHEDULE 13G |
| 2026-08-14 | TCG Crossover GP I, LLC | 2.7% | SCHEDULE 13G/A |
| 2026-09-10 | MPM BioVentures 2014, L.P. | 9.9% | SCHEDULE 13D/A |
Questions about who owns Entrada Therapeutics, Inc.
Who owns Entrada Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Entrada Therapeutics, Inc.: 5AM Ventures V, L.P. (10.8%, Schedule 13D/A, filed 2025-11-18) and MPM BioVentures 2014, L.P. (9.9%, Schedule 13D/A, filed 2026-09-10).
Who are the largest shareholders of Entrada Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Entrada Therapeutics, Inc. on this page are 5AM Ventures V, L.P. (10.8%) and MPM BioVentures 2014, L.P. (9.9%).
When did 5AM Ventures V, L.P. buy into Entrada Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from 5AM Ventures V, L.P. on this page is the Schedule 13D/A, filed 2025-11-18, reporting 10.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Entrada Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.